Emerging small molecule drugs by Colin, Sophie et al.
 
 
 University of Groningen
Emerging small molecule drugs
Colin, Sophie; Chinetti-Gbaguidi, Giulia; Kuivenhoven, Jan A; Staels, Bart
Published in:
Handbook of Experimental Pharmacology
DOI:
10.1007/978-3-319-09665-0_20
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2015
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Colin, S., Chinetti-Gbaguidi, G., Kuivenhoven, J. A., & Staels, B. (2015). Emerging small molecule drugs.
Handbook of Experimental Pharmacology, 224, 617-630. https://doi.org/10.1007/978-3-319-09665-0_20
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
Emerging Small Molecule Drugs
Sophie Colin, Giulia Chinetti-Gbaguidi, Jan A. Kuivenhoven,
and Bart Staels
Contents
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 618
2 Cholesteryl Ester Transfer Protein Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619
2.1 Biological Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619
2.2 Current State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 619
2.3 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 620
3 Novel PPAR Agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621
3.1 Biological Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 621
3.2 Current State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622
3.3 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 622
4 Novel LXR Agonists . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.1 Biological Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 623
4.2 Current State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624
4.3 Future Perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 624
5 RVX-208 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
5.1 Biological Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
5.2 Current State . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 625
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 626
S. Colin • G. Chinetti-Gbaguidi • B. Staels (*)
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Abstract
Dyslipidaemia is a major risk factor for cardiovascular diseases. Pharmacologi-
cal lowering of LDL-C levels using statins reduces cardiovascular risk. How-
ever, a substantial residual risk persists especially in patients with type 2 diabetes
mellitus. Because of the inverse association observed in epidemiological studies
of HDL-C with the risk for cardiovascular diseases, novel therapeutic strategies
to raise HDL-C levels or improve HDL functionality are developed as comple-
mentary therapy for cardiovascular diseases. However, until now most therapies
targeting HDL-C levels failed in clinical trials because of side effects or absence
of clinical benefits. This chapter will highlight the emerging small molecules
currently developed and tested in clinical trials to pharmacologically modulate
HDL-C and functionality including new CETP inhibitors (anacetrapib,
evacetrapib), novel PPAR agonists (K-877, CER-002, DSP-8658, INT131 and
GFT505), LXR agonists (ATI-111, LXR-623, XL-652) and RVX-208.
Keywords
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Abbreviations
ABCA1 ATP-binding cassette transporter A1
ABCG1 ATP-binding cassette transporter G1
ACC Acetyl-CoA carboxylase
Apo apolipoprotein
CETP Cholesteryl ester transfer protein
CVD Cardiovascular disease
FAS Fatty acid synthase
HDL High-density lipoprotein
LDL Low-density lipoprotein
LXR Liver X receptor
MTTP Microsomal triglyceride transfer protein
PPAR Peroxisome proliferator-activated receptor
PCSK9 Proprotein convertase subtilisin/kexin type 9
SCD-1 Stearoyl-CoA desaturase-1
SREBP-1 Sterol regulatory element-binding protein
1 Introduction
Dyslipidaemia is a major risk factor for cardiovascular diseases, a main cause of
morbidity and mortality worldwide, with 17.3 million deaths per year (Laslett
et al. 2012). LDL-C-lowering therapy, especially with statins, has shown to be an
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efficient approach to reduce cardiovascular risk on average by 25–35 %. Although
lowering LDL-C with statins has beneficial effects and reduces cardiovascular
events, significant numbers of residual cardiovascular events remain in high-risk
patients, prompting the search for alternative complementary approaches. Among
these strategies, new agents combined with statins, such as proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors, microsomal triglyceride transfer protein
(MTTP) inhibitors or ezetimibe can provide additional lowering LDL-C effects.
Because HDL-C levels are inversely correlated with cardiovascular risk (Gordon
et al. 1977), raising HDL-C levels has spawned high hopes as additional therapy for
cardiovascular diseases. However, so far none of the pharmacological interventions
aimed at raising HDL-C levels has yielded convincing results with respect to
reduction of cardiovascular risk.
In this chapter we will focus on these emerging small molecule drugs in
development, including cholesteryl ester transfer protein (CETP) inhibitors, novel
peroxisome proliferator-activated receptor (PPAR) agonists, liver X receptor
(LXR) agonists and RVX-208. For each drug, the biological mechanisms of these
molecules, an overview of the current state of the clinical trials and the future
perspectives will be provided.
2 Cholesteryl Ester Transfer Protein Inhibitors
2.1 Biological Mechanisms
The cholesteryl ester transfer protein (CETP) promotes the transfer of triglycerides
from apoB-containing lipoproteins (LDL, IDL and VLDL) to HDL-C in exchange
for cholesteryl esters. Interest in CETP inhibitor development came from studies in
families with CETP deficiency with hyperalphalipoproteinaemia CETP deficiency
(Inazu 1990) and epidemiological studies showing that CETP gene variants are
associated with increased HDL-C levels and a lower risk of coronary heart disease
events (Curb et al. 2004).
2.2 Current State
Four CETP inhibitors have been developed in humans: torcetrapib, anacetrapib,
dalcetrapib and evacetrapib. The first CETP inhibitor designed by Pfizer and tested
in phase III clinical trials was torcetrapib. The initial results of the ILLUMINATE
(Investigation of Lipid Level Management to Understand its Impact in Atheroscle-
rotic Events) trial were encouraging, with a 72 % increase in HDL-C and a 25 %
decrease in LDL-C in patients with high CVD risk treated with torcetrapib on top of
atorvastatin (Kastelein et al. 2007). However, all studies were interrupted because
of an increased risk of cardiovascular events and an excess of mortality upon
torcetrapib usage, possibly due to an increase in aldosterone level and blood
pressure (Barter et al. 2007). Further analyses have demonstrated that the effect
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on blood pressure was independent of CETP inhibition. Indeed, torcetrapib
increases blood pressure in mice that do not express CETP (Forrest et al. 2008).
Furthermore, genetic association studies in 58,948 subjects with polymorphism in
CETP gene report that CETP genotype was not associated with systolic nor
diastolic blood pressure (Sofat et al. 2010). These results suggest that toxicity
upon torcetrapib treatment could be CETP independent.
Even though the dal-OUTCOMES trial with dalcetrapib (Roche) showed an
increase of HDL-C by 30 %, the results showed futility and trials were halted due to
the absence of obvious benefit (Schwartz et al. 2012). Furthermore, the effect of
dalcetrapib on vessel wall structure and vascular inflammation was investigated
after a 2-year treatment in the dal-PLAQUE trial (Fayad et al. 2011). No significant
benefit was reported in dalcetrapib-treated patients, but in patients with low HDL-C
at baseline, beneficial effects on endothelial function were observed. However, in
the dal-VESSEL study, designed to validate these results, the beneficial effects
were not confirmed (Lüscher et al. 2012). Nevertheless, despite these failures, no
vascular toxicity and blood pressure increase were observed on top of dalcetrapib
treatment (Lüscher et al. 2012). Based on these results, two other more potent CETP
inhibitors, anacetrapib and evacetrapib, have been developed and are still in phase
III clinical trials.
2.3 Future Perspectives
Anacetrapib is a potent CETP inhibitor developed by Merck. In a first clinical trial,
anacetrapib increased HDL-C by 138 % and reduced LDL-C by 40 % in patients
with coronary artery disease or at high risk for coronary heart disease on statin
therapy. This clinical trial with the acronym DEFINE (Determining the EFficacy
and Tolerability of CETP Inhibition with Anacetrapib), demonstrated the safety of
anacetrapib and absence of significant changes in blood pressure, aldosterone and
electrolyte levels (Cannon et al. 2010). Currently, a phase III clinical trial is
ongoing, acronym REVEAL (Randomized EValuation of the Effects of
Anacetrapib Through Lipid-modification), which will determine whether lipid
modification on anacetrapib therapy reduces the risk of coronary death, myocardial
infarction (MI) or coronary revascularisation in patients with circulatory problems
and low LDL-C on statin therapy (ClinicalTrials.gov identifier: NCT01252953).
The results of this trial are expected at the beginning of 2017.
Evacetrapib, designed by Eli Lilly & Company, is the fourth member of the
CETP inhibitor class that is tested in clinical trials. A phase II clinical trial
evaluated the efficacy of evacetrapib as monotherapy or in combination with the
most prescribed statins in patients with either hypercholesterolaemia or low HDL-C
levels. As monotherapy, evacetrapib (30 mg, 100 mg or 500 mg/day) dose-
dependently reduced LDL-C from 14 to 36 % and increased HDL-C from 54 to
129 %. Although the decrease of LDL-C was higher in combination with statins
(49 % vs. 24 %), the increase of HDL-C was not stronger when compared to
evacetrapib monotherapy (Nicholls et al. 2011). No adverse effects were observed
in this trial, with no changes in blood pressure or aldosterone levels. Thus
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evacetrapib appears to be well-tolerated (Nicholls et al. 2011). The benefits of
evacetrapib in combination with statins will be determined in a phase III
randomised outcome trial, acronym ACCELERATE (Assessment of Clinical
Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients
at a High-Risk for Vascular Outcomes) (Estimated end date: January 2016;
ClinicalTrials.gov identifier: NCT01687998).
3 Novel PPAR Agonists
3.1 Biological Mechanisms
Peroxisome proliferator-activated receptors (PPARs) are a nuclear receptor sub-
family with three members, PPARα, PPARγ and PPARβ/δ, encoded by distinct
genes. The three isoforms display distinct patterns of expression with PPARα being
highly expressed in liver, kidney, heart, muscle and brown adipose tissue, PPARγ is
most abundant in adipose tissue, whereas PPARβ/δ is ubiquitously expressed
(Lefebvre et al. 2006). Upon heterodimerisation with the retinoic X receptor,
PPARs bind to PPAR response elements (PPRE) located in the promoters of their
target genes and thus exert negative or positive control on their transcription.
The role of PPARα was initially studied in the liver where it enhances fatty acid
oxidation, regulates gluconeogenesis through an increase of pyruvate dehydroge-
nase kinase 4 expression and ketone body production in response to the fasting
state. Through its natural ligands, such as long-chain unsaturated fatty acids,
arachidonic acid derivatives and oxidised phospholipids, PPARα regulates also
some genes involved in lipid and lipoprotein metabolism. The increase of apoAV
and lipoprotein lipase expression by PPARα activation associated with the reduc-
tion of apoCIII expression contributes to reduced plasma triglyceride levels in
humans. Moreover, plasma HDL cholesterol levels increase as a result of the
stimulation of two major HDL-associated apolipoproteins, apoAI and apoAII, by
PPARα (Staels et al. 1998). In addition to these hepatic effects, PPARα activation
enhances reverse cholesterol transport related to the increase of ATP-binding
cassette transporter A1 (ABCA1) in macrophages (Chinetti et al. 2001) and exerts
many pleiotropic effects on vascular remodelling and inflammatory responses.
PPARγ is activated by natural ligands such as polyunsaturated fatty acids,
15-deoxy-Δ12,14-prostaglandin J2 and oxidised fatty acids. In addition, pharmaco-
logical PPARγ agonists, the thiazolidinediones, are used as insulin sensitisers.
Furthermore, PPARγ is the major regulator of adipogenesis (Tontonoz and
Spiegelman 2008). PPARγ regulates the expression of adipokines such as
adiponectin (Yu et al. 2002). In addition to this adipogenic effect, PPARγ displays
anti-inflammatory actions and promotes the polarisation of monocytes towards
alternative M2 macrophages (Bouhlel et al. 2007).
PPARβ/δ is activated by long-chain unsaturated fatty acids, and several syn-
thetic ligands have been designed including L-165041, GW501516 and GW0742.
However, no PPARβ/δ agonists are in clinical use yet. PPARβ/δ is highly expressed
in skeletal muscle where it increases the expression of fatty acid oxidation-related
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genes. This nuclear receptor also improves lipid metabolism by reducing
triglycerides and LDL-C levels and by increasing HDL-C levels. Moreover,
PPARβ/δ activation increases insulin sensitivity (Oliver et al. 2001).
Overall, PPARs are involved in the control of lipid lipoprotein and glucose
metabolism as well as in the inflammatory response (Lefebvre et al. 2006).
3.2 Current State
Among the pharmacologically used PPARα ligands are the fibrates, which are
currently clinically used as hypolipidaemic drugs. Clinical benefits of fibrates
were reported in primary and secondary intervention trials and reviewed in a
meta-analysis (Jun et al. 2010). In line with their capacity to increase HDL-C and
reduce triglycerides and LDL-C (Jun et al. 2010), their effects on the incidence of
coronary heart disease appear most pronounced in patients with high triglycerides
(>200 mg/dL) and/or low HDL-C (<40 mg/dL), although this has not yet been
formally proven in a dedicated trial in type 2 diabetes patients (Suh et al. 2012;
Keech et al. 2005).
Each PPAR isoform displays specific roles, with PPARα controlling lipid
metabolism, whereas PPARδ improves also glucose metabolism. An interesting
strategy consisted in the development of dual agonists with synergistic effects on
different PPAR isoforms and minimal side effects (Rosenson et al. 2012). In this
context, Roche developed a dual PPAR α/γ agonist, aleglitazar. Despite promising
results in the synchrony study, with an improvement of lipid and glucose
parameters in type 2 diabetes patients (Henry et al. 2009), the AleCardio phase
III trial failed due to adverse effects on heart failure. Subsequently, all trials with
aleglitazar were stopped (press report: http://www.roche.com/media/media_
releases/med-cor-2013-07-10.htm).
3.3 Future Perspectives
Some limitations of fibrate therapy are their relatively weak activity on PPARα and
their efficacy that depends on the targeted population (Staels 2010). To address
these issues, several highly selective and potent PPAR agonists were developed
(Fruchart 2013). The KOWA Company is developing K-877, a potent PPARα
agonist. In a comparative clinical trial (International Clinical Trials identifier:
JPRN-JapicCTI-121764), patients with hypertriglyceridaemia and low HDL-C
were treated with K-877 or fenofibrate for 12 weeks. The first results showed that
the increase of HDL-C is stronger by K-877 than by fenofibrate. In addition, none of
the adverse effects induced by fenofibrate, such as increased levels of serum
homocysteine and creatinine, were observed in K-877-treated patients (http://
www.kenes.com/eas2012/abstracts/pdf/525.pdf). This molecule is currently in
phase II in the USA and EU (International Clinical Trials identifier:
EUCTR2013-001517-32-SE) and in phase III clinical trials for atherosclerotic
dyslipidaemia in Japan (International Clinical Trials identifier: JPRN-JapicCTI-
132067).
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A HDL-inducer developed by Cerenis Therapeutics is a specific PPARδ agonist,
CER-002. The phase I clinical trial demonstrated that CER-002 is well-tolerated
without major adverse effects (press report: http://www.drugs.com/clinical_trials/
cerenis-therapeutics-announces-successful-completion-phase-clinical-trial-cer-
002-cardiovascular-4272.html). Another selective PPARδ agonist, HPP593, is cur-
rently tested in healthy subjects, and its effect on LDL and HDL cholesterol as well as
triglycerides will be determined (press report: http://www.ttpharma.com/
TherapeuticAreas/MetabolicDisorders/Dyslipidemia/HPP593/tabid/118/Default.aspx).
The synthetic, non-thiazolidinedione PPARγ compound, INT131, improves
glucose tolerance in rodent models of diabetes to a similar extent as rosiglitazone.
However, no major adverse events, such as weight gain, haemodilution or plasma
volume increase, were observed in INT131-treated rats compared to rosiglitazone-
treated rats (Motani et al. 2009). In a randomised, double-blind study, type 2 diabe-
tes patients were treated 4 weeks with 1 or 10 mg of INT131. Consistent with the
in vitro data, INT131 displayed a glucose-lowering activity and increased HDL-C
levels without changing other lipid parameters (Dunn et al. 2011). This molecule is
currently tested in a comparative clinical study in type 2 diabetes patients treated
for 24 weeks with INT131 or pioglitazone (ClinicalTrials.gov Identifier:
NCT00631007).
In addition, a phase I clinical trial is ongoing to evaluate safety, tolerability and
pharmacokinetic behaviour of a new PPAR α/γ modulator, DSP-8658, in type
2 diabetes mellitus and healthy subjects (ClinicalTrials.gov Identifier:
NCT01042106). DSP-8658 is a non-thiazolidinedione compound which exhibits
potent anti-hyperglycaemic effects, reduces plasma triglycerides and increases
HDL-C levels with less side effects on, e.g., body weight gain (press report:
www.ds-pharma.com/ir/library/presentation/pdf).
Finally, the new dual PPAR α/δ agonist GFT505, developed by Genfit, reduced
plasma triglycerides and increased HDL-C levels in abdominally obese patients
with either dyslipidaemia or prediabetes (Cariou et al. 2011). A phase IIb clinical
trial is ongoing to evaluate the efficacy of GFT505 in patients with non-alcoholic
steatohepatitis (ClinicalTrials.gov identifier: NCT01694849), an unmet clinical
need because of the continuous increasing incidence of fatty liver disease due to
abdominal obesity (Tailleux et al. 2012).
These novel selective PPAR agonists, K-877, CER-002, DSP-8658, INT131 and
GFT505 appear promising drugs to treat the cardiovascular risk associated with
metabolic syndrome and type 2 diabetes.
4 Novel LXR Agonists
4.1 Biological Mechanisms
Liver X receptors (LXRs) are nuclear receptors. There are two isoforms, LXRα and
LXRβ, with LXRα mainly expressed in the liver, intestine, kidney and spleen,
whereas LXRβ is ubiquitously expressed (Repa and Mangelsdorf 2000). Oxysterols
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and other cholesterol metabolites are natural ligands for LXRs, and several syn-
thetic ligands were also developed (T0901317, GW3965). After their binding,
LXRs modulate the expression of genes involved in cholesterol metabolism and
transport and glucose metabolism (Schultz et al. 2000; Laffitte et al. 2003). Activa-
tion of LXR in macrophages induces ABCA1, ABCG1 and apoE expression which
promotes cholesterol efflux and reverses cholesterol transport (Sabol et al. 2005;
Venkateswaran et al. 2000; Laffitte et al. 2001). Besides their effects on lipid
metabolism, LXRs display anti-inflammatory properties (Joseph et al. 2003) and
improve glucose tolerance. In contrast to their beneficial effects, LXR activation
induces fatty acid synthesis (de novo lipogenesis) related to a modulation of the
hepatic expression of sterol regulatory element-binding protein (SREBP-1),
stearoyl-CoA desaturase-1 (SCD-1), fatty acid synthase (FAS) and acetyl-CoA
carboxylase (ACC) (Schultz et al. 2000). This upregulation of hepatic SREBP-1c
expression may contribute to the elevation of plasma triglycerides.
4.2 Current State
T0901317 and GW3965, the most studied agonists, have been extensively
described to exert beneficial effects in preclinical animal models of cardiovascular
diseases, neurodegenerative diseases and inflammation (Terasaka et al. 2003;
Joseph et al. 2002, 2003; Zelcer et al. 2007). However, LXR ligands have not yet
been tested in clinical trials because of their adverse effects such as an increase of
hepatic lipogenesis, hypertriglyceridaemia and hepatosteatosis (Calkin and
Tontonoz 2012). These lipogenic effects have been assigned to LXRα which is
highly expressed in the liver (Lehrke et al. 2005; Bradley et al. 2007). Therapeutic
strategies are now focusing on the development of selective LXR modulators,
LXRβ-specific agonists and/or ligands which act selectively in specific tissues in
order to maintain positive effects on cholesterol metabolism and minimise the lipid
side effects.
LXR-623 (WAY-252623) is a novel synthetic ligand with higher potency for
LXRβ, which induces plaque regression in combination with statins in a rabbit
model of atherosclerosis (Giannarelli et al. 2012). LXR-623 entered in a phase I
trial (NCT00366522) to test tolerance and safety in humans (Katz et al. 2009).
However, its development was interrupted because of adverse effects in the central
nervous system with potential induction of psychiatric disorders.
4.3 Future Perspectives
A novel synthetic, steroidal LXR ligand, ATI-111, has been developed. This mole-
cule is most potent on LXRα with modest effects on LXRβ. The higher efficiency on
LXRα allows its utilisation at lower concentrations than T0901317, which probably
reduces cytotoxicity and also adverse effects such as hypertriglyceridaemia. To
determine whether ATI-111 does not provoke hypertriglyceridaemia, mice were
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treated with 5 mg.kg-1.day-1 of ATI-111 for 8 weeks. Interestingly, a decrease of
plasma triglyceride levels and VLDL cholesterol was observed in ATI-111-treated
mice (Peng et al. 2011). In addition, ATI-111 exhibits anti-inflammatory properties
with a decrease of LPS-induced inflammatory gene expression. Furthermore,
ATI-111 reduced atherosclerotic lesions in LDL-receptor-deficient mice (Peng
et al. 2011). Altogether, accumulating proofs from in vitro and in vivo animal studies
show beneficial effects of ATI-111 on atherosclerosis with anti-inflammatory effects,
a reduction of hypertriglyceridaemia and a consequential decrease of atherosclerotic
lesions. Further molecular investigations are necessary to assess the full potential of
ATI-111 in clinical trials.
A phase I clinical trial with XL-652 (XL-014), a novel LXR ligand, is currently
ongoing to evaluate its safety (www.exelixis.com/pipeline/xl652).
5 RVX-208
5.1 Biological Mechanisms
An alternative strategy to raise the serum level of HDL-C is to increase one of the
major HDL proteins, apolipoprotein AI (apoAI). In this context, after a screening
assay in HepG2 cells to identify molecules inducing apoAI, Resverlogix Corpora-
tion has selected and developed an oral quinazoline molecule, RVX-208
(RVX-000222). This molecule, a derivative of resveratrol, increases hepatic
apoAI production (Bailey et al. 2010). Thus RVX-208 is a small molecule for
potential treatment of cardiovascular diseases.
5.2 Current State
First in vitro experiments have shown that RVX-208 increases apoAI mRNA,
protein and the release of apoAI in the medium of HepG2 cells (Bailey
et al. 2010). To test its efficiency in vivo, male monkeys were orally treated with
RVX-208 for 63 days. This in vivo study in nonhuman primates demonstrated that
RVX-208 increases in a dose-dependent manner serum levels of apoAI and pre-
β-HDL-C (Bailey et al. 2010). No adverse effects were observed in monkeys. In
humans, 7 days of treatment increased preβ-HDL, apoAI and cholesterol efflux
(Bailey et al. 2010). The efficacy and safety of RVX-208 was furthermore
investigated in a phase II randomised trial including 299 statin-treated patients
with coronary artery diseases (ASSERT study: NTC01058018). Twice daily admin-
istration of RVX-208 (50, 100 and 150 mg) was well tolerated; however, a transient
elevation in transaminase levels was found in some RVX-208-treated patients.
Furthermore, only a modest increase of HDL-C level (3.2–8.3 %) was observed
(Nicholls et al. 2011). In a next phase IIb clinical study, the ASSURE (ApoAI
Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma
Regression Evaluation) trial, the effect of 26 weeks treatment with RVX-208
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(100 mg) was determined on the progression of coronary atherosclerosis in
323 patients with symptomatic coronary artery disease and low HDL-C levels.
The primary end point, change in atheroma volume determined by intravascular
ultrasound (IVUS), was not met. No significant change in plaque regression was
observed between placebo and RVX-208 group. The question is whether this lack
of beneficial effect on plaque regression is due to the weak efficacy of RVX-208 or
the impossibility to confer beneficial effects on top of statins, since 84 % of patients
were on statin therapy. Furthermore, the increases of apoAI and HDL-C levels did
not differ from placebo, whereas transaminases were again found to be elevated.
Thus, so far, no clinical benefit has been demonstrated with RVX-208 (press report:
communication Nicholls SJ www.clinicaltrialresults.org/Nicholls_ASSURE).
Conclusion
To reduce residual cardiovascular risk persisting after statin therapy, novel
therapeutic strategies based on raising HDL-C are currently under investigation.
However, the utility of increasing HDL-C is not yet established, and pharma-
ceutical manipulation of HDL-C appears to be less efficient than lowering
LDL-C to reduce cardiovascular risk. Moreover, the failure of several clinical
trials with the first members of the CETP inhibitor class, torcetrapib and
dalcetrapib, and the lack of beneficial effects of an increase of HDL-C and the
reduction of cardiovascular events raises doubts about the relevance of the
“HDL-C hypothesis”. These disappointing results highlight the complexity of
HDL metabolism in contrast to that of LDL.
Many biological activities of HDL, such as antioxidant, anti-inflammatory
and antiapoptotic properties, are mediated by different HDL subclasses, and
solely increasing HDL-C may not enhance these functions. Moreover, plasma
HDL contains heterogeneous particle subpopulations whose composition,
metabolism and functionality differ depending on the metabolic status (Besler
et al. 2011). Thus far, the larger randomised placebo controlled phase III clinical
trials have shown that an increase in HDL-C does not benefit the patient, and
thus, future strategies should aim at improving HDL function.
Open Access This chapter is distributed under the terms of the Creative Commons Attribution
Noncommercial License, which permits any noncommercial use, distribution, and reproduction in
any medium, provided the original author(s) and source are credited.
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